Archimed has agreed to acquire Ann Arbor, Michigan-based Esperion Therapeutics (Nasdaq: ESPR) in a transaction valued at up to approximately USD 1.1 billion in total equity value on a fully diluted basis, assuming full achievement of all commercial milestones. The deal gives the French healthcare-focused investment firm direct ownership of Esperion's US commercial infrastructure built around bempedoic acid, an ATP-citrate lyase (ACLY) inhibitor, along with retained rights in China, Canada, and other unlicensed markets.
Under the terms of the merger agreement, an affiliate of Archimed will acquire all outstanding Esperion shares at USD 3.16 per share in cash at closing, representing a 58% premium to Esperion's closing share price on April 30, 2026. Each shareholder also receives one non-tradeable contingent value right (CVR) entitling them to participate in up to USD 100 million in aggregate contingent milestone payments structured across two tranches. The first tranche delivers up to USD 40 million tied to US annual net sales of bempedoic acid-containing products — Nexletol (bempedoic acid) and Nexlizet (bempedoic acid/ezetimibe) — in calendar year 2027, with full payment triggered if those sales exceed USD 350 million and linear interpolation applied between USD 300 million and USD 350 million. The second tranche delivers USD 60 million if US annual net sales of bumetanide-containing products, including Enbumyst (bumetanide nasal spray), reach or exceed USD 160 million in any single calendar year through December 31, 2030. Deal closing is expected in the third quarter of 2026, subject to Esperion shareholder approval and required regulatory clearances.
Nexletol and Nexlizet are oral, once-daily, non-statin therapies indicated for LDL-C reduction in patients at elevated cardiovascular risk. Both products target ACLY, an enzyme upstream of HMG-CoA reductase in the cholesterol biosynthesis pathway, thereby reducing hepatic cholesterol synthesis without direct statin mechanism engagement. Enbumyst, a nasal spray formulation of bumetanide, represents Esperion's expansion into rare and orphan disease indications, though the press release does not specify the approved indication or current sales trajectory for this asset. Esperion holds full US commercial rights to all three products, which constitute the basis for both CVR tranches and the core commercial rationale for the acquisition.
The geographic structure of the deal reflects a layered rights profile that Archimed inherits. In Europe, Daiichi Sankyo Europe holds exclusive commercialization rights to the bempedoic acid franchise, with Esperion entitled to tiered royalties of 15–25% on European net sales. Esperion previously monetized that royalty stream to OMERS, which receives payments until achieving 1.7x its investment, after which the royalty reverts to Esperion — and thus to Archimed post-closing. In Japan, Otsuka Pharmaceutical holds exclusive development and commercialization rights under a licensing agreement originally valued at USD 510 million; Esperion similarly pre-sold its current royalty interest and milestone entitlements from Otsuka's Japanese sales to Athyrium Capital for USD 50 million, subject to a cap, with residual reversionary interest transferring to Archimed. China, Canada, and other markets where Esperion has not established commercial partnerships transfer to Archimed as wholly owned, undeveloped rights.